Shares of Regenxbio Inc. (NASDAQ:RGNX) saw strong trading volume on Friday . 117,660 shares changed hands during trading, an increase of 13% from the previous session’s volume of 104,151 shares.The stock last traded at $11.18 and had previously closed at $9.97.

A number of analysts recently issued reports on the company. Zacks Investment Research lowered Regenxbio from a “hold” rating to a “sell” rating in a research note on Friday. Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a research note on Tuesday, May 10th. Finally, Piper Jaffray Cos. reiterated a “buy” rating and set a $33.00 price objective on shares of Regenxbio in a research note on Tuesday, July 5th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $28.35.

The firm has a 50-day moving average price of $8.33 and a 200 day moving average price of $10.96. The firm’s market cap is $304.35 million.

Regenxbio (NASDAQ:RGNX) last posted its earnings results on Tuesday, August 9th. The company reported ($0.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.02. Equities research analysts predict that Regenxbio Inc. will post ($2.31) earnings per share for the current fiscal year.

In other Regenxbio news, insider Fmr Llc sold 18,300 shares of Regenxbio stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $12.41, for a total value of $227,103.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

An institutional investor recently raised its position in Regenxbio stock. RS Investment Management Co. LLC raised its position in Regenxbio Inc. (NASDAQ:RGNX) by 11.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 746,592 shares of the company’s stock after buying an additional 75,810 shares during the period. RS Investment Management Co. LLC owned 2.84% of Regenxbio worth $12,393,000 as of its most recent filing with the SEC.

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.